Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prepping For Brexit With Notified Body Switch Could Be Unnecessary Expense, BSI Warns

Executive Summary

While there are some warnings that UK medical device companies should be jumping ship, and taking worst-case Brexit scenarios seriously, major notified body BSI believes there is too much scaremongering, and that a less disruptive EU-UK agreement is likely.

You may also be interested in...

BSI Touts 'Very Short' Waiting Times For Migrating Certificates From UK To Netherlands

With a growing urgency for medtech manufacturers to take decisive action so their products are not banned from the market under an increasingly likely no-deal Brexit, clients of BSI will be relieved to hear their notified body believes time is on their side.

Brexit: Where Things Stand For Medtech

UK and EU leaders announced some progress on Brexit this week, establishing a conditional transition period after the UK exits the Union in 2019. But that does not resolve many questions and concerns in the medtech space about what's to come. Here is a comprehensive look at where things stand for medtech, based a discussion from this week's Device Week podcast.

EU Regulatory Reads, January 2018: Brexit And New Reg-Deadline Minefields

2018 has had a bumpy start in the realm of EU regulations. The tangled Brexit issue has some in industry playing Russian roulette, while other deadlines are causing concerns. These issues and more were covered in the most popular Medtech Insight EU regulation stories from January.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts